| |
| |
|
| Insider
Information: |
Secora Michael |
| Relationship: |
Chief Financial Officer |
| City: |
Salt Lake City |
| State: |
UT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,219,093 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,593,574 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,219,093 |
|
|
| Total
Value |
$11,593,574 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Recursion Pharmaceuticals, Inc. |
RXRX |
Chief Financial Officer |
2024-05-15 |
1,219,093 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
149,077 |
528,762 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
528,762 |
528,762 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2022-02-04 |
4/A |
A |
$0.00 |
$0 |
D/D |
60,299 |
591,058 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
60,299 |
590,449 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
210,163 |
798,237 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
182,849 |
1,163,863 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-06-13 |
4 |
AS |
$9.93 |
$248,308 |
D/D |
(25,000) |
805,413 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-06-14 |
4 |
AS |
$10.07 |
$251,838 |
D/D |
(25,000) |
817,913 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-07-18 |
4 |
AS |
$13.62 |
$340,802 |
D/D |
(25,000) |
830,413 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-07-19 |
4 |
AS |
$14.36 |
$388,348 |
D/D |
(25,000) |
842,913 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-08-15 |
4 |
AS |
$9.27 |
$231,793 |
D/D |
(25,000) |
850,686 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-08-16 |
4 |
AS |
$8.90 |
$222,518 |
D/D |
(25,000) |
863,186 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-09-12 |
4 |
AS |
$8.43 |
$210,633 |
D/D |
(25,000) |
875,686 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-09-13 |
4 |
AS |
$8.69 |
$217,318 |
D/D |
(25,000) |
888,186 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-10-10 |
4 |
AS |
$7.07 |
$176,763 |
D/D |
(25,000) |
900,686 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-10-11 |
4 |
AS |
$6.85 |
$171,313 |
D/D |
(25,000) |
913,186 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-11-14 |
4 |
AS |
$6.32 |
$157,943 |
D/D |
(25,000) |
925,686 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-11-15 |
4 |
AS |
$7.25 |
$182,986 |
D/D |
(25,000) |
938,186 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-12-12 |
4 |
AS |
$7.39 |
$184,868 |
D/D |
(25,000) |
943,514 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-12-13 |
4 |
AS |
$7.59 |
$189,770 |
D/D |
(25,000) |
956,014 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-01-16 |
4 |
AS |
$10.45 |
$261,160 |
D/D |
(25,000) |
968,514 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-01-17 |
4 |
AS |
$10.25 |
$256,348 |
D/D |
(25,000) |
981,014 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-02-13 |
4 |
AS |
$9.86 |
$246,560 |
D/D |
(25,000) |
1,173,851 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-02-14 |
4 |
AS |
$10.43 |
$261,425 |
D/D |
(25,000) |
1,186,351 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-03-12 |
4 |
AS |
$10.46 |
$261,375 |
D/D |
(25,000) |
1,191,679 |
0 |
% |
|
65 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
